L. Liu

Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas

S. Goldsmith, L. Liu, Kevin Shiah, 2022, Current opinion in oncology.

Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein–Barr Virus (EBV) Assessments—A Single Tertiary Referral Center Experience and Review of Literature

C. Chen, R. Chinnock, Matthew Kim, 2021, Cancers.

Letermovir discontinuation at D+100 after Allogeneic Stem Cell Transplant is associated with increased CMV-related mortality.

F. Gao, R. Vij, P. Westervelt, 2022, Transplantation and cellular therapy.

The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis

Y. Tao, A. Hirbe, Xiao Zhang, 2022, Genes.

A rash in a hairy situation: Leukocytoclastic vasculitis at presentation of hairy cell Leukemia

S. Ossowski, J. Moyers, H. Cao, 2019, American journal of hematology.

A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma

F. Gao, R. Vij, M. Fiala, 2021, Leukemia & lymphoma.